论文部分内容阅读
全球抗结核药品管理中心(GDF)是一个旨在提高高质量抗结核药品使用率的新行动。作为日内瓦世界卫生组织(WHO)遏制结核病全球合作伙伴组织的项目之一,GDF由该合作伙伴的秘书处进行管理。其目标是在未来5年对高达1160万的病人提供抗结核药品,并帮助某些国家实现WHO的2005年全球结核病控制目标。GDF于2001年3月24日启动,已经完成了6轮申请,46个国家和非政府组织(NGOs)得到支持。GDF摈弃传统的采购机制。通过把药品需求与药品供应和药品监测相联系,利用合作伙伴提供服务,采用产品剂量包装简化药品管理,并将药品支持与结核病项目实施相联系等,GDF采用全新的药品供应方法。本文描述GDF的操作程序和迄 今为止所获得的经验,并概括了所取得的主要成就,包括建立了一个灵活的供应系统以满足不同项目需求,快速建立了采购程序,降低了抗结核药品的价格——这是国家DOTS扩展的催化剂,产品的标准化以及与合作伙伴的良好协作。GDF非常灵活,可以满足结核病负担国家的需求。GDF的经验也可以作为其它疾病如HIV/AIDS和疟疾,全球性药品和商品采购的范例。GDF的活动内容将来可能扩展到包括二线抗结核药品以及诊断材料,并且可以协助其他合作伙伴建立类似机制和机构以满足国家需求。
The Global Anti-TB Drug Management Center (GDF) is a new initiative aimed at increasing the use of high-quality anti-TB drugs. As part of the World Health Organization (WHO) Global Partnership against Tuberculosis in Geneva, the GDF is managed by the secretariat of the partner. The goal is to provide up to 11.6 million patients with anti-TB drugs over the next five years and to help some countries achieve the WHO’s 2005 global TB control goals. The GDF was launched on March 24, 2001, and six rounds of applications have been completed. 46 countries and non-governmental organizations (NGOs) are supported. GDF abandon the traditional procurement mechanism. GDF has adopted a new approach to drug delivery by linking drug demand to drug supply and drug monitoring, utilizing partners to deliver services, adopting product-dose packaging to streamline drug administration and linking drug support to tuberculosis project implementation. This article describes the GDF’s operating procedures and lessons learned to date and summarizes the major achievements made, including the establishment of a flexible supply system to meet the needs of different projects, the rapid establishment of procurement procedures and the reduction of the price of anti-TB drugs - This is a catalyst for national DOTS expansion, product standardization and good collaboration with partners. GDFs are flexible enough to meet the needs of countries with a burden of TB. The GDF’s experience can also serve as an example of other diseases such as HIV / AIDS and malaria, a global purchase of medicines and commodities. The GDF’s activities may be expanded to include second-line anti-TB drugs and diagnostic materials in the future and other partners may be assisted in setting up similar mechanisms and institutions to meet national needs.